These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31738571)

  • 1. Short-term effect of pharmacologically induced alterations in testosterone levels on common blood biomarkers in a controlled healthy human model.
    Sahlin KB; Pla I; Sanchez A; Pawłowski K; Leijonhufvud I; Appelqvist R; Marko-Varga G; Giwercman A; Malm J
    Scand J Clin Lab Invest; 2020 Feb; 80(1):25-31. PubMed ID: 31738571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
    Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
    Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men.
    Rolf C; Gottschalk I; Behre HM; Rauch C; Thyroff U; Nieschlag E
    Exp Clin Endocrinol Diabetes; 1999; 107(1):63-9. PubMed ID: 10077358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men.
    Bagatell CJ; Conn PM; Bremner WJ
    Fertil Steril; 1993 Oct; 60(4):680-5. PubMed ID: 8405525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men.
    Giwercman A; Sahlin KB; Pla Parada I; Pawlowski K; Fehninger C; Lundberg Giwercman Y; Leijonhufvud I; Appelqvist R; Marko-Varga G; Sanchez A; Malm J
    Elife; 2022 Mar; 11():. PubMed ID: 35230239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the endocrine manifestations of hepatic cirrhosis.
    Baker HW; Burger HG; de Kretser DM; Dulmanis A; Hudson B; O'Connor S; Paulsen CA; Purcell N; Rennie GC; Seah CS; Taft HP; Wang C
    Q J Med; 1976 Jan; 45(177):145-78. PubMed ID: 769039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of androgen deficiency and replacement on prostate zonal volumes.
    Jin B; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
    Behre HM; Böckers A; Schlingheider A; Nieschlag E
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):241-8. PubMed ID: 8137524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN; Debold CR; Island DP; Wakefield G; Rivier J; Vale W; Rabin D
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological and biochemical changes after boldenone injection in adult rabbits.
    Tousson E; El-Moghazy M; Massoud A; El-Atrash A; Sweef O; Akel A
    Toxicol Ind Health; 2016 Jan; 32(1):177-82. PubMed ID: 24081634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF; Rollet J
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect and safety of testosterone undecanoate in the treatment of late-onset hypogonadism: a meta-analysis].
    Zheng Y; Shen XB; Zhou YZ; Ma J; Shang XJ; Shi YJ
    Zhonghua Nan Ke Xue; 2015 Mar; 21(3):263-71. PubMed ID: 25898560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.
    Behre HM; Kliesch S; Pühse G; Reissmann T; Nieschlag E
    J Clin Endocrinol Metab; 1997 May; 82(5):1403-8. PubMed ID: 9141524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men.
    Bagatell CJ; McLachlan RI; de Kretser DM; Burger HG; Vale WW; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1989 Jul; 69(1):43-8. PubMed ID: 2499592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.